Rivian heads into Tuesday's Q1 print down 9% on the week and 8.4% in a single session — a sharp move that has left the stock lagging its EV peer group.
The price drop stands out against the broader EV landscape. Tesla gained 2.1% on the week and LCID added 1.6%, while Rivian was the clear underperformer. That one-day plunge to $15.02 — reached without an obvious catalyst — sets a tense backdrop for a report due after the close on May 5. Notably, Rivian's two most recent earnings prints each triggered single-day declines of around 5-6%, so the market has a reasonably consistent track record of selling the news.
Despite the stock's weakness, short sellers are not pressing harder into the earnings window. Short interest edged up just 0.9% on the week to 11.5% of the free float — a structurally elevated level, but down roughly 7 percentage points from the highs posted in early April, when shorts topped 12.8% of float. The borrow market is equally relaxed: cost to borrow runs at under 0.5%, and availability is well supplied, with around 58% of borrowed shares still available to lend. That is not the profile of a heavily crowded short ahead of a binary event. The ORTEX short score sits at 69.3 — high in absolute terms, but it has barely moved in two weeks, suggesting the short community is watching rather than adding.
Options positioning adds another wrinkle. The put/call ratio has dropped sharply to 0.91, now running nearly 2.6 standard deviations below its 20-day mean of 1.0 — the most call-heavy reading in the recent window. That means options traders are rotating into calls even as the stock falls, either chasing a post-earnings bounce or positioning for a relief rally if guidance holds. For a stock that has fallen 8% in a day, the absence of fresh put demand is notable.
The analyst debate heading in is less about direction and more about magnitude of recovery. Benchmark and Needham both reiterate Buy ratings with $23-$25 targets, implying 55-65% upside from current levels. BNP Paribas trims its target one dollar to $22 while keeping Outperform, and Cantor Fitzgerald nudges its Neutral target up to $19 — a split picture where bulls see the selloff as an entry point and neutrals see limited near-term catalysts to close the gap. The bear case centres on competitive intensity, the capital demands of vertical integration, and the challenge of scaling against larger, better-capitalised rivals. The mean target of $18.20 implies roughly 21% upside — reasonable on paper, but the stock has spent much of the past three months circling $15.
CEO Robert Scaringe has sold shares steadily across March and April — three separate transactions totalling roughly $1.1M — alongside CFO Claire McDonough's late-April sale. These are plan-driven sales in modest size, not alarm bells, but the insider register shows no buying to offset them.
The Q1 print will test whether the production ramp, VW partnership progress, and any improvement in gross margin can give bulls a concrete reason to close that gap between $15 and the analyst consensus — or whether the recurring pattern of post-earnings selling reasserts itself.
See the live data behind this article on ORTEX.
Open RIVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
